Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 16, 2020 01:00 ET | Source: NeuroRx

NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19

With resurgent COVID-19, enrollment has accelerated in Miami, Houston, and Irvine Data Monitoring Committee determined that so far RLF-100 has generated no drug-related Serious Adverse Events or other...
June 24, 2020 01:30 ET | Source: NeuroRx

NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19

Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these...
June 11, 2020 01:00 ET | Source: NeuroRx

Relief Therapeutics and NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 Patients with Respiratory Failure to Houston Methodist Hospital

Clinical trial to enroll 144 patients total with expansion to additional sitesClinical trial expanded to patients treated with both noninvasive and mechanical ventilation in Critical COVID-19.RLF-100...
June 08, 2020 01:00 ET | Source: NeuroRx

Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure

Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in critical COVID-19Clinical trial to enroll 144 patients total with expansion to additional sites RLF-100...
June 01, 2020 16:03 ET | Source: NeuroRx

Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress

First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100Clinical trial to enroll 144 patients total with expansion to additional sites including the...
May 14, 2020 01:00 ET | Source: NeuroRx

Relief Therapeutics and NeuroRx Announce Final Manufacturing Validation of RLF-100 for Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress Syndrome

Study to enroll 144 patients with COVID-19 who have progressed to Acute Respiratory Distress and require intensive care with mechanical ventilationRLF-100 is a patented formulation of Aviptadil...